IDEAYA Biosciences, Inc. IDYA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| External Clinical Development Expenses by Product | ||||||
| Darovasertib | $23.33M+1.4% | $23.25M-14.6% | $26.88M+103% | $25.09M+68.5% | $23.02M+112% | |
| IDE034 | $6.81M+17,816% | $837K— | —— | —— | $38K— | |
| IDE161 | $1.61M-34.4% | $1.79M-65.9% | $1.79M-26.4% | $1.57M-23.8% | $2.45M-9.2% | |
| IDE397 | $3.52M-6.0% | $3.43M-54.3% | $3.7M-26.9% | $3.79M-6.7% | $3.74M+27.9% | |
| IDE574 | $3.05M+375% | $1.43M— | —— | —— | $643K— | |
| IDE849 | $4.77M+1,026% | $6.91M-63.2% | —— | —— | $423K-97.7% | |
| IDE892 | $2.18M+153% | $2.27M— | —— | —— | $860K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does IDEAYA Biosciences, Inc. break its business down?
- IDEAYA Biosciences, Inc. (IDYA) reports external clinical development expenses by product across 7 parts — Darovasertib, IDE034, IDE161, IDE397 and IDE574. Each is extracted from the segment footnotes and tracked over time.
- Where does IDEAYA Biosciences, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in IDEAYA Biosciences, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
